Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib alone or with ebastine in advanced or metastatic renal cell carcinoma
CTR20191111Phase 3Active
- Sponsor
- NA/ 精鼎医药研究开发（上海）有限公司
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pazopanib, eribulin in renal cell carcinoma (RCC), sponsored by NA/ 精鼎医药研究开发（上海）有限公司. Started Jul 2019; status: active.
02
Drugs
pazopaniberibulin
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20191111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191111.